Merrimack Pharmaceuticals News

Merrimack Pharmaceuticals | 15-12G: Notice of termination of registration of a class of securities under Section 12(g) (and amendment thereto)

May 20 15:13

Merrimack Pharmaceuticals | 10-Q: Quarterly report

May 15 21:44

Merrimack Pharmaceuticals | 25: Notification of the removal from listing and registration of matured, redeemed or retired securities (and amendment thereto)

May 10 15:49

Merrimack Pharmaceuticals | 8-K: Current report

May 10 15:45

Merrimack Pharmaceuticals | DEFA14A: Others

May 9 06:47

Merrimack Pharmaceuticals | 8-K: Current report

May 9 06:47

Merrimack Pharmaceuticals | DEFA14A: Others

Apr 30 16:28

Merrimack Pharmaceuticals | 8-K: Current report

Apr 30 16:27

Merrimack Pharmaceuticals | DEFR14A: Definitive proxy statement in connection with contested solicitations

Apr 1 15:36

Merrimack Pharmaceuticals | DEFA14A: Others

Mar 27 16:05

Merrimack Pharmaceuticals | 8-K: Current report

Mar 27 16:00

Merrimack Pharmaceuticals | DEFA14A: Others

Mar 22 08:47

Merrimack Pharmaceuticals | DEF 14A: Definitive information statements

Mar 21 15:58

Merrimack Pharmaceuticals | 10-K/A: Annual report (Amendment)

Mar 21 15:52

Merrimack Pharmaceuticals | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Mar 7 15:46

Merrimack Pharmaceuticals | 8-K: Current report

Mar 7 15:41

Merrimack Pharmaceuticals | 10-K: Annual report

Mar 7 15:22

Merrimack Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(4.99%)

Mar 7 11:36

Merrimack Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Mar 5 15:52

Merrimack Pharmaceuticals | SCHEDULE 13G: Others

Feb 22 15:50